OABI - NASDAQ

OmniAb, Inc.

OABI·NASDAQ

$2.50

-4.6%

HealthcareBiotechnology

OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$297.73M

EPS-0.5700

P/E Ratio-4.39

Earnings Date08/05/2026

300.91M

Assets

-8%

3Y-29.0%

5Y+2.0%

10Y+15.0%

33.89M

Total Liabilities

-11%

3Y-58.0%

5Y-43.0%

10Y-23.0%

267.03M

Total Equity

-7%

3Y-22.0%

5Y+13.0%

10Y+22.0%

OmniAb, Inc. Funding & Solvency Profile

OABI · NASDAQ

Current Assets

Cash & Cash Equivalents25.52M

Net Receivables7.39M

Inventory0.00

Other Current Assets3.93M

Total Current Assets65 M

Non-Current Assets

Property, Plant & Equipment24.97M

Goodwill & Intangible Assets209.13M

Long-Term Investments0.00

Other Non-Current Assets1.47M

Total Non-Current Assets26 M

Total Assets

300.91M

Financial Health Analysis

Current Ratio

4.02x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.13x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

49 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

22% Current

Capital-intensive business with significant long-term investments in property, equipment, or intangibles.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

OmniAb, Inc. Balance Sheet

OABI • NASDAQ

OmniAb, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	25.5M	27.6M	16.4M	33.4M	0.0	0.0	0.0
Short-Term Investments	28.5M	31.8M	70.6M	54.9M	0.0	0.0	0.0
Cash & Short-Term Investments	54M	59.4M	87M	88.3M	0.0	0.0	0.0
Net Receivables	7.4M	5.3M	3.8M	30.3M	21.1M	15.9M	7.8M
Accounts Receivables	7.4M	5.3M	3.8M	30.3M	21.1M	15.9M	7.8M
Other Current Assets	3.9M	3.4M	4.1M	6.4M	1.4M	774K	21K
Total Current Assets	65.3M	68.1M	94.9M	125M	22.5M	16.6M	7.8M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	25M	33.3M	38.1M	41.5M	20.1M	6M	4.3M
Goodwill	84M	84M	84M	84M	84M	84M	77.1M
Intangible Assets	125.1M	138.1M	155.5M	167.2M	176.3M	186.6M	173M
Goodwill & Intangible Assets	209.1M	222M	239.4M	251.2M	260.3M	270.6M	250.1M
Other Non-Current Assets	1.5M	2.1M	2.7M	3.6M	1.5M	2.1M	115K
Total Non-Current Assets	235.6M	257.4M	280.3M	296.3M	281.9M	278.7M	254.5M
Total Assets	300.9M	325.6M	375.2M	421.2M	304.5M	295.4M	262.3M
LIABILITIES
CURRENT LIABILITIES
Total Payables	1.9M	2.3M	4.4M	6.5M	3.9M	2M	806K
Accounts Payable	1.9M	2.3M	4.4M	3M	2.9M	469K	806K
Other Payables	0.0	0.0	0.0	3.5M	1M	1.5M	0.0
Accrued Expenses	0.0	0.0	570K	1.4M	363K	776K	487K
Short Term Debt	3.9M	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	3.8M	3.5M	1.8M	578K	580K	300K
Tax Payables	0.0	0.0	0.0	3.5M	0.0	0.0	0.0
Deferred Revenue	3.2M	2.3M	6.8M	8.2M	10.8M	7.2M	0.0
Other Current Liabilities	7.3M	6.7M	7.8M	8.2M	4.9M	3.8M	4.5M
Total Current Liabilities	16.3M	15.1M	23.1M	26M	20.6M	14.3M	6.1M
NON-CURRENT LIABILITIES
Deferred Revenue (Non-Current)	0.0	117K	862K	4.3M	9.2M	8.2M	0.0
Deferred Tax Liabilities (Non-Current)	785K	2.3M	11.4M	21.3M	22M	28.9M	0.0
Other Non-Current Liabilities	393K	1M	3.2M	4.1M	5.1M	6.4M	35.7M
Total Non-Current Liabilities	17.6M	22.9M	37.5M	53.8M	49.6M	45.6M	38M
Capital Lease Obligations	16.5M	23.2M	25.6M	25.8M	13.9M	2.6M	2.6M
Total Liabilities	33.9M	37.9M	60.6M	79.8M	70.2M	59.8M	44.1M
SHAREHOLDERS' EQUITY
Common Stock	14K	12K	12K	12K	0.0	0.0	218.2M
Additional Paid-In Capital	433.2M	389M	353.9M	330.1M	0.0	0.0	0.0
Retained Earnings	-166.2M	-101.4M	-39.4M	11.3M	0.0	0.0	0.0
Accumulated Other Comprehensive Income/Loss	12K	27K	50K	9K	0.0	0.0	0.0
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	234.3M	235.5M	0.0
Total Stockholders' Equity	267M	287.6M	314.6M	341.4M	234.3M	235.5M	218.2M
Total Equity	267M	287.6M	314.6M	341.4M	234.3M	235.5M	218.2M
SUMMARY
Total Liabilities & Equity	300.9M	325.6M	375.2M	421.2M	304.5M	295.4M	262.3M
Total Investments	28.5M	31.8M	70.6M	54.9M	0.0	0.0	0.0
Total Debt	20.3M	23.2M	25.6M	25.8M	13.9M	2.6M	2.3M
Net Debt	-5.2M	-4.4M	9.2M	-7.6M	13.9M	2.6M	2.3M
Shares Outstanding	122,758,112	122,758,112	122,758,112	122,758,112	122,758,112	122,758,112	122,758,112

SEC Filings

OABI - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 07, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 07, 2026	May 07, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 29, 2026	June 17, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 04, 2026	March 04, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 04, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	January 30, 2026	January 30, 2026	2026	View Filing
10-Q 10-Q 2025 Q3 Q3	November 04, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 04, 2025	November 04, 2025	2025	View Filing
S-3 S-3 N/A	September 12, 2025	September 12, 2025		View Filing
8-K 8-K 2025 N/A	August 25, 2025	August 24, 2025	2025	View Filing

Showing 1 to 10 of 78 filings

Related Guides

Blog Categories

Continue your OABI research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.